RTI Health Solutions

🌟 Empowering the Next Generation of Women in STEM! 🌟
We're proud to share that Mei Grace, Sr Research Health Economist at RTI-HS, spoke at Girls Talk Math at UNC Chapel Hill, inspiring students with her STEM journey. Her story sparked curiosity, engagement, and highlighted the power of mentorship.

RTI Health Solutions Recognized for Sustainable Management System RTI Health Solutions has earned a Bronze Medal, a recognition awarded to the Top 35% of companies assessed by EcoVadis for the sustainability of the company's management system and commitment to promo...

We’re proud to announce that we have earned a Bronze Medal Sustainability Rating from EcoVadis. This is a testament to our commitment to incorporate sustainable practices into our operations, ensuring we positively impact the environment and society. Learn more at ow.ly/zXj350WnUi1

A New Era of Collaboration for EU Health Technology Assessment Learn about developments in the EU HTA regulation and the role of collaboration, AI, and capacity building in shaping the future of healthcare.

There was an invigorating atmosphere of cooperation at the recent focusing on the 6-month assessment of new EU HTA, JCA regulation. Several of our researchers attended and share key insights. Read their observations here: ow.ly/HM1750WmB2Q 🧪 PharmSky Medsky HTA

Webinar: Surrogate Outcomes in Health Technology Assessment - Accelerating Access to Breakthrough Treatments Surrogate outcomes play an important role in modern healthcare research. Join us for this webinar where our experts will focus on methods and guidelines for establishing surrogate outcomes and how the...

Next week on June 18, our experts will be hosting a webinar where they discuss methods and guidelines for establishing surrogate outcomes. Learn how they have been used in health technology assessments to date. Register today! ow.ly/BA9r50VOqLt 🧪 PharmSky Medsky HTA

Artificial Intelligence in Health Science: Advancing Research Responsibly and Ethically While the use of artificial intelligence holds great promise, it also comes with risk. We help clients understand how to effectively use AI in their research.

There's a lot of debate surrounding the use of artificial intelligence tools in research. At RTI Health Solutions, we prioritize responsible #AI use by adhering to these 5 key principles. ow.ly/riV150W3f6c Responsible AI, Human in the Loop, pharmaceutical development

Joint Clinical Assessment and Orphan Drugs: 5 Steps to Success JCAs will apply to orphan medicines starting in 2028. We’d like to share some of what we’ve learned from working on JCA submissions.

RTI-HS experts share 5 critical steps during rare disease drug development that can help prepare your orphan drug to progress through joint clinical assessments (JCA). ow.ly/Q28e50VVWOJ 🧪 PharmSky Medsky

Hi Chris! Welcome to Bluesky. So glad you're here. 😃 - Samantha @csimmons913.bsky.social

Why Implementation Science is Vital for Pharma Innovation Learn how implementation science helps pharma improve adoption, outcomes, and value by embedding sustainable strategies into existing workflows.

Discover how the pharmaceutical industry can leverage implementation science to identify gaps and opportunities, enabling companies to craft research that aligns with long-term goals and delivers tangible value to all decision-makers. ow.ly/LAHU50VSPQS 🧪 PharmSky Medsky #ISPORAnnual

Webinar: Surrogate Outcomes in Health Technology Assessment - Accelerating Access to Breakthrough Treatments Surrogate outcomes play an important role in modern healthcare research. Join us for this webinar where our experts will focus on methods and guidelines for establishing surrogate outcomes and how the...

You are invited to our June 18 webinar: Surrogate Outcomes in HTA. Explore real-world examples and challenges around using surrogate outcomes in HTAs, with examples in cardiovascular disease, oncology, and obesity. Learn more and register here ow.ly/BA9r50VOqLt 🧪 PharmSky Medsky

Recognizing Futility in Research: When to Consider Discontinuing Observational Research Learn the signs of research futility, from data limitations to ethical concerns, and when to discontinue observational studies for scientific integrity.

Learn the signs of research futility, from data limitations to ethical concerns, and when to discontinue observational studies for scientific integrity. ow.ly/viaY50V2PES @John Seeger #observationalresearch #researchethics 🧪PharmSky #realworldevidence

RTI recognized by Newsweek as one of America’s Greenest Companies RTI was recognized as one of America’s Greenest Companies by Newsweek and Plant-A Insights Group in collaboration with GIST Impact.

We are very proud that RTI has been recognized as one of America's Greenest Companies by Newsweek! We are serious about our commitment to corporate responsibility and #sustainability. Read more about this award. ow.ly/R1s550TWITy 🧪 PharmSky @rti.bsky.social

Harnessing AI Tools for Enhanced Evidence Synthesis: Lessons Learned AI holds immense potential to address one of the most significant challenges in evidence synthesis: the sheer volume of work. See more.

The responsible use of AI tools in evidence synthesis is paramount. Thorough evaluation before deployment ensures that tools enhance efficiency without compromising quality. Jose Marcano Belisario, PhD of RTI Health Solutions shares his insights. ow.ly/myTL50VGjRf #ResponsibleAI 🧪 PharmSky Medsky

How Getting Sick Can Cost You Billions Our experts discuss the complete economic burden of this disease and how you can stay healthy this winter.

Listen in on a discussion of research aimed at informing policy decisions around the prevention and care of RSV. The study reveals a considerable physical burden of RSV across the U.S. along with staggering costs. ow.ly/iP9v50UV78Y @AURN - American Urban Radio Networks 🧪 PharmSky Medsky

Joint Clinical Assessment Rules on Health Tech Assessment Now in Effect: New Era for Patient Access to Innovation The EU’s health technology assessment framework, effective from January 2025, improves patient access to new cancer medicines and advanced therapies.

It's a new era for patient access to health innovation. The EU Commission's Joint Clinical Assessment Rules on HTA are now in effect. Learn about what this era heralds: ow.ly/ImgU50UFFBI #JCA #jointclinicalassessment #patientaccess PharmSky HEOR

Therapeutic Research – Are We Asking the Right Questions? This article explores strategies and approaches to refining a research question, offering a guide to help researchers craft improved questions. See more.

Are we asking the right questions to inform therapeutic research? John Seeger, PharmD, DrPH shares the steps to create a research question can serve as a compass, driving research in a productive and meaningful way. Read on- ow.ly/4jsj50VA3ZR 🧪 PharmSky Medsky Drug Research medical device research

Award for Best Cost-Effectiveness Analysis Published in 2024 RTI-HS authors' research on HIV drugs has been named Paper of the Year by CEVR.

We are thrilled that research on cost-effectiveness of HIV pre-exposure prophylaxis drugs coauthored by RTI-HS' Anita Brogan and Ashley Davis has been awarded Paper of the Year by CEVR. Learn more about the research - ow.ly/sSFF50VALTX 🧪 PharmSky Medsky Drug Research @tuftscevr.bsky.social

RTI Health Solutions Welcomes AJ Messina as Head of Implementation Science AJ Messina has joined RTI-HS where he will play a key role in advancing Implementation Science within pharmaceutical research and development. Learn more.

Welcome AJ Messina to RTI-HS as Head of Implementation Science! A recognized leader within pharma, AJ has been instrumental in bridging the gap between drug development and real-world adoption. We’re excited to have AJ on board! ow.ly/tN2250VocaC #pharmaceuticals 🧪 PharmSky

The recording is here! If you missed our webinar on unlocking the full potential of literature reviews in your pharmaceutical or health technology asset development, you can watch it here-> ow.ly/i9Cn50V63Lm #pharmaceutical #healthtechnology #litreviews

Pave the Way to Joint Clinical Assessment for Your Orphan Drug in Europe Learn how the 2028 Joint Clinical Assessment changes impact orphan drug approvals in Europe and how strategic planning can improve market success.

In January 2028, a new era begins for orphan product manufacturers in Europe with Joint Clinical Assessments. Learn how changes will impact orphan drug approvals and how strategic planning can improve market success. ow.ly/T3GM50VhbOQ 🧪 PharmSky Medsky #JCA drug approval

Recognizing Futility in Research: When to Consider Discontinuing Observational Research Learn the signs of research futility, from data limitations to ethical concerns, and when to discontinue observational studies for scientific integrity.

Learn the signs of research futility, from data limitations to ethical concerns, and when to discontinue observational studies for scientific integrity. ow.ly/viaY50V2PES written by John Seeger #observationalresearch #researchethics 🧪 PharmSky Medsky

Ten Must‐Read Papers on Transparency and Reproducibility in Pharmacoepidemiology ow.ly/wgGL50VeMG How can we ensure quality and establish trust in research? Our contributions on the topic are featured in the PRINCIPLED and DIVERSE frameworks, and the HARPER protocol template 🧪 PharmSky Medsky

In-Person Course: Towards Regulatory-Grade Causal Inference from Observational Data Bring your causal questions about real-world data to the experts

2 day course on Causal Inference from Observational Data. Includes practical use-case studies that apply to the target trial framework. Submit questions about your own target trial emulations. Learn more at ow.ly/3e4250UOSa0 #targettrial #epidemiology #biostatistics #causalinference 🧪

Recognizing Futility in Research: When to Consider Discontinuing Observational Research Learn the signs of research futility, from data limitations to ethical concerns, and when to discontinue observational studies for scientific integrity.

Learn to recognize the signs of research futility, from data limitations to ethical concerns, and when to discontinue observational studies for scientific integrity. ow.ly/viaY50V2PES #observationalresearch #researchethics 🧪PharmSky #realworldevidence

Webinar: Using Literature Reviews to Reveal the Benefits and Demonstrate the Value of Your Product​ Unlock the full potential of leveraging literature reviews in your pharmaceutical or health technology asset development strategy by joining our upcoming webinar. Gain valuable insights into various a...

Unlock the full potential of leveraging literature reviews in your pharmaceutical or health technology asset development strategy by joining our upcoming webinar. Learn more and register here. ow.ly/i9Cn50V63Lm #drugdevelopment #healthtech #litreviews

Text: Maximize your data for health outcomes, regulatory, and safety research. On blue background with RTI-HS logo.

If you are working on health research studies with UK data, who is accessing, managing, and interpreting that data for you? Our researchers can determine whether CPRD data may be the best option for your research questions. ow.ly/fpc750UR4oT #realworldevidence #realworlddata 🧪PharmSky

Rethinking Health Technology Assessment: Expanding Value Beyond Health Gains and Costs Learn how new frameworks for HTAs can better capture the full value of medical innovations, including broader social impacts.

It’s no longer enough to assess benefits and costs to healthcare payers; we must also capture broader societal effects on patients, families, and the economy. New HTA frameworks can better capture the value of medical innovations. #HealthTechnologyAssessment #HEOR 🧪 PharmSky #HealthEconomics

Optimizing Health Economic Modelling for Multicountry Adaptations Learn how to streamline health economic models for multicountry adaptations, ensuring efficiency, compliance, and cost-effectiveness in HTA submissions.

Decision Modelling for health economic evaluation has challenges when it comes to multicountry adaptations. Learn how streamlining model adaptations for #HTA submissions can bring efficiencies & compliance. ow.ly/L3N550USlJU #HealthTechnologyAssessment #HEOR 🧪 PharmSky #HealthEconomics #HEModelling

In-Person Course: Towards Regulatory-Grade Causal Inference from Observational Data Bring your causal questions about real-world data to the experts

@causalab.bsky.social and @rtihs.bsky.social invite you to this 2-day in-person course. Learn from case studies that apply to the target trial framework and ask questions about your own target trial emulations. Learn more and register at ow.ly/3e4250UOSa0 epidemiology biostatistics causal inference